<DOC>
	<DOCNO>NCT00087386</DOCNO>
	<brief_summary>This phase II trial study well tanespimycin work treat patient stage III stage IV melanoma . Antitumor antibiotic tanespimycin may stop growth melanoma stop blood flow tumor .</brief_summary>
	<brief_title>Tanespimycin Treating Patients With Stage III-IV Melanoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine treatment 17-AAG result measurable anti-tumor effect calculate proportion clinical response . II . Test hypothesis treatment 17-AAG disrupt MAPK pathway deplete intra-tumor store RAF kinase and/or downstream protein phospho-ERK , CDK4 cyclin D1 . III . Determine either effect correlate presence mutate BRAF within melanoma tumor . OUTLINE : This multicenter study . Patients stratify accord presence BRAF mutation tumor ( yes v ) . Patients receive tanespimycin IV 1-6 hour weekly 6 week . Courses repeat every 56 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically cytologically confirm melanoma Stage III IV disease No primary melanoma choroid mucosa Measurable disease At least 1 unidimensionally measurable lesion &gt; = 20 mm conventional technique OR &gt; = 10 mm spiral CT scan Tumor amenable biopsy ( first 10 patient stratum ) Patients must measurable disease addition tumor ( ) biopsied No brain epidural metastasis Completely resect solitary brain metastasis allow provided patient free CNS metastases &gt; = 6 month Performance status Karnofsky 60100 % Performance status ECOG 02 More 3 month Absolute neutrophil count &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 WBC &gt; = 3,000/mm^3 AST ALT = &lt; 2.5 time upper limit normal Creatinine normal No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No history myocardial infarction No history prolong QTc interval No active ischemic heart disease within past 12 month No uncontrolled dysrhythmia dysrhythmias require medication No congenital prolong QT syndrome No leave bundle branch block Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction attribute compound similar chemical biological composition 17Nallylamino17demethoxygeldanamycin ( 17AAG ) No prior serious allergic reaction egg No uncontrolled illness No active ongoing infection require systemic antimicrobial treatment No psychiatric illness social situation would preclude study compliance No 1 prior chemotherapy regimen metastatic melanoma Prior vaccine , cytokine , interferon alfa consider prior therapy unless administer chemotherapy drug More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Prior radiotherapy dose = &lt; 3,000 cGy field include substantial marrow More 4 week since prior radiotherapy recover No prior radiotherapy field include heart ( e.g. , mantle ) No concurrent combination antiretroviral therapy HIVpositive patient No concurrent medication may prolong QTc interval No concurrent anticancer therapy No concurrent investigational agent No concurrent treatment follow medication herbal remedy : Inhibitors CYP3A4 : Fluconazole Itraconazole Ketoconazole Macrolide antibiotic ( azithromycin , clarithromycin , erythromycin , troleandomycin ) Midazolam Nifedipine Verapamil Diltiazem Terfenadine Cyclosporine Cisapride Inducers CYP3A4 : Carbamazepine Phenobarbital Phenytoin Rifampin Herbal extract tincture CYP3A4 inhibitory activity : Hydrastis canadensis ( goldenseal ) Hypericum perforatum ( St. John 's wort ) Uncaria tomentosa ( cat 's claw ) Echinacea angustifolia root Trifolium pratense ( wild cherry ) Matricaria chamomilla ( chamomile ) Glycyrrhiza glabra ( licorice ) Dillapiol Hypericin Naringin No concurrent herbal extract</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>